Current and future challenges of subcutaneous and sublingual allergy immunotherapy for allergists in the United States

Both subcutaneous and sublingual allergy immunotherapy (SCIT and SLIT, respectively) for inhalant allergens have proven efficacy for allergic rhinitis and allergic asthma, with limited support for efficacy in selected patients with atopic dermatitis.1 Both SCIT and SLIT have been shown to modify the immunologic defect underlying the allergic respiratory diseases,2 an effect that is clinically manifest by suppression of new sensitization in monosensitized patients, reduction in the development of asthma in those only having allergic rhinitis, and persistence of clinical improvement for years after an adequate course of treatment.

https://ift.tt/2l3AsmB